newsfilter
← Latest News
GlobeNewswire·

Galapagos NV Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to GLPG5101 for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma

Mechelen, Belgium; August 6, 2025, 7:30 CET; regulated information – inside information – Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced that the United States Food and Drug Administration (FDA) has granted